Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses

Clinical Immunology

Volumn 139, Issue 2, 2011, Pages 155-163

  Speletas, Matthaios ^a   Argentou, Nikoletta ^a   Karanikas, Vaios ^a   Gramoustianou, Evangelia S ^a   Mandala, Eudokia ^b   Braimi, Margarita ^c   Matsouka, Panagiota ^a   Ritis, Konstantinos ^a,d   Germenis, Anastasios E ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Chronic myeloid leukemia; Cytolytic responses; Imatinib; Survivin

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; ISOPROTEIN; NILOTINIB; SURVIVIN;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER GROWTH; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CYTOLYSIS; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RELAPSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELLS; BONE MARROW CELLS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPITOPES, T-LYMPHOCYTE; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PIPERAZINES; PROTEIN ISOFORMS; PYRIMIDINES; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79954583618     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.01.010     Document Type: Article

References (45)

1. Cortes J., O'Brien S., Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004, 104:2204-2205.
2. Usuki K., Iijima K., Iki S., Urabe A. CML cytogenetic relapse after cessation of imatinib therapy. Leuk Res 2005, 29:237-238.
3. Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., Amabile M., Forconi F., Gozzetti A., Raspadori D., Amadori S., Lauria F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365:657-662.
4. Smith B.D., Kasamon Y.L., Kowalski J., Gocke C., Murphy K., Miller C.B., Garrett-Mayer E., Tsai H.L., Qin L., Chia C., Biedrzycki B., Harding T.C., Tu G.H., Jones R., Hege K., Levitsky H.I. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010, 16:338-347.
5. Shinozawa I., Inokuchi K., Wakabayashi I., Dan K. Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. Leuk Res 2000, 24:965-970.
6. Contea E., Stagnob F., Guglielmob P., Scutoa A., Consolib C., Messina A. Survivin expression in chronic myeloid leukemia. Cancer Lett 2005, 225:105-110.
7. Hernandez-Boluda J.C., Bellosillo B., Vela M.C., Colomer D., Alvarez-Larran A., Cervantes F. Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma 2005, 46:717-722.
8. Schwartz J., Pinilla-Ibarz J., Yuan R.R., Scheinberg D.A. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol 2003, 40:87-96.
9. Ambrosini G., Adida C., Altieri D.C. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
10. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
11. Carter B.Z., Milella M., Altieri D.C., Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001, 97:2784-2790.
12. Creutzig U., Harbott J., Scholz F., Creutzig U., Harbott J., Scholz F., Karawajew L., Ludwig W.D., Wuchter C. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004, 10:3737-3744.
13. Wang Z., Sampath J., Fukuda S., Pelus L.M. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res 2005, 65:8224-8232.
14. Carter B.Z., Mak D.H., Schober W.D., Cabreira-Hansen M., Beran M., McQueen T., Chen W., Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006, 107:1555-1563.
15. Duffy M.J., O'Donovanc N., Brennand D.J., Gallagherd W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett 2007, 249:49-60.
16. Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999, 59:6097-6102.
17. Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T., Inuzuka M. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 2004, 314:902-907.
18. Caldas H., Honsey L.E., Altura R.A. Survivin 2a: a novel survivin splice variant expressed in human malignancies. Mol Cancer 2005, 4:11.
19. Zhu N., Gu L., Findley H.W., Li F., Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 2004, 23:7545-7551.
20. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cavé H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., van Dongen J.J. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
21. Karanikas V., Tsochas S., Boukas K., Kerenidi T., Nakou M., Dahabreh J., Poularakis T., Gourgoulianis K.I., Germenis A.E. Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer Biol Ther 2008, 7:1-8.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDCT) method. Methods 2001, 25:402-408.
23. Ritis K., Doumas M., Mastellos D., Micheli A., Giaglis S., Magotti P., Rafail S., Kartalis G., Sideras P., Lambris J.D. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006, 177:4794-4802.
24. Coughlin C.M., Leming F., Carroll R.G., Pawel B.R., Hogarty M.D., Shan X., Vance B.A., Cohen J.N., Jairaj S., Lord E.M., Wexler M.H., Danet-Desnoyers G.A., Pinkus J.L., Pinkus G.S., Maris J.M., Grupp S.A., Vonderheide R.H. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006, 24:5725-5734.
25. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.B., Becker J.C., thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001, 61:5964-5968.
26. Hirohashi Y., Torigoe T., Maeda A., Nabeta Y., Kamiguchi K., Sato T., Yoda J., Ikeda H., Hirata K., Yamanaka N., Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002, 8:1731-1739.
27. Karanikas V., Soukou F., Kalala F., Kerenidi T., Grammoustianou E.S., Gourgoulianis K.I., Germenis A.E. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol 2008, 129:230-240.
28. Baccarani M., Castagnetti F., Gugliotta G., Palandri F., Soverini S. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol 2009, 22:331-341.
29. Badran A., Yoshida A., Wano Y., Imamura S., Kawai Y., Tsutani H., Inuzuka M., Ueda T. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res 2003, 23:589-592.
30. Mahotka C., Krieg T., Krieg A., Wenzel M., Suschek C.V., Heydthausen M., Gabbert H.E., Gerharz C.D. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002, 100:30-36.
31. Krieg A., Mahotka C., Krieg T., Grabsch H., Muller W., Takeno S., Suschek C.V., Heydthausen M., Gabbert H.E., Gerharz C.D. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumor progression. Br J Cancer 2002, 86:737-743.
32. Ling X., Yang J., Tan D., Ramnath N., Younis T., Bundy B.N., Slocum H.K., Yang L., Zhou M., Li F. Differential expression of survivin-2B and survivin-Dex3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer. Lung Cancer 2005, 49:353-361.
33. Zaffaroni N., Pennat M., Colella G., Perego P., Supino R., Gatti L., Pilotti S., Daidone F.M.G. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002, 59:1406-1412.
34. Span P.N., Tjan-Heijnen V.C., Manders P., van Tienoven C., Lehr J., Sweep F.C. High survivin predicts a poor response to endocrine therapy but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 2006, 98:223-230.
35. Kanwar J.R., Shen W.P., Kanwar R.K., Berg R.W., Krissansen G.W. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001, 93:1541-1552.
36. Lucas C.M., Harris R.J., Giannoudis A., Davies A., Knight K., Watmough S.J., Wang L., Clark R.E. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 2009, 94:1362-1367.
37. Gianani R., Jarboe E., Orlicky D., Frost M., Bobak J., Lehner R., Shroyer K.R. Expression of survivin in normal, hyperplastic and neoplastic colonic tissue. Hum Pathol 2001, 42:119-125.
38. Gurbuxani S., Xu Y., Keerthivasan G., Wickrema A., Crispino J.D. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci USA 2005, 102:11480-11485.
39. Xing Z., Conway E.M., Kang C., Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004, 199:69-80.
40. Fukuda S., Pelus L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001, 98:2091-2100.
41. Mesri M., Morales-Ruiz M., Ackermann E.J., Bennett C.F., Pober J.S., Sessa W.C., Altieri D.C. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001, 158:1757-1765.
42. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006, 5:1087-1098.
43. Karanikas V., Khalil S., Kerenidi T., Gourgoulianis K.I., Germenis A.E. Anti-survivin antibody responses in lung cancer. Cancer Lett 2009, 281:159-166.
44. Tanaka S., Harada M., Mine T., Noguchi M., Gohara R., Azuma K., Tamura M., Yamada A., Morinaga A., Nishikori M., Katagiri K., Itoh K., Yamana H., Hashimoto T. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 2003, 26:357-366.
45. Rizzuto G.A., Merghoub T., Hirschhorn-Cymerman D., Liu C., Lesokhin A.M., Sahawneh D., Zhong H., Panageas K.S., Perales M.A., Altan-Bonnet G., Wolchok J.D., Houghton A.N. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009, 206:849-866.